U.S. markets open in 1 hour 3 minutes

Impel NeuroPharma, Inc. (IMPL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.05-0.46 (-4.84%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close9.51
Open9.53
Bid0.00 x 1400
Ask0.00 x 900
Day's Range9.05 - 10.06
52 Week Range9.01 - 15.89
Volume58,227
Avg. Volume147,956
Market Cap201.601M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
    GlobeNewswire

    Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference

    SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET. A live webcast, if recorded, of the presentation can be acc

  • Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update
    GlobeNewswire

    Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

    – Completed successful IPO raising approximately $80.0 million in gross proceeds –– NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –– Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems – SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and c

  • Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society
    GlobeNewswire

    Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society

    Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including Nausea and Nasal and Cardiovascular Safety as a Promising Potential New Option for the Treatment of Acute Migraine Attacks SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies